Alzheimer's drug approved despite murky results
Kelly Servick
Abstract
FDA breaks from advisers to clear aducanumab based on reduction of toxic brain plaques.
Topics & Concepts
DrugMedicinePharmacologyScience, Research, and Medicine
Kelly Servick
FDA breaks from advisers to clear aducanumab based on reduction of toxic brain plaques.